The Effient Launch: Cracking The Door To Primary Care Marketing
This article was originally published in The Pink Sheet Daily
Executive Summary
Latest edition of The IN VIVO Blog podcast suggests a positive, perhaps counterintuitive, take on the impact of Effient's black box warning.
You may also be interested in...
Effient Labeling Could Give Edge Against Plavix Through Pharmacogenetics
Lilly/Daiichi Sankyo's prasugrel has carefully constructed label to control risk of bleeding - but it also includes a pharmacogenetic argument that Effient works in clopidogrel non-responders.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.